Cencora (COR) Raises 2026 EPS Outlook After Revenue Miss as International Growth Outpaces Domestic

Cencora, Inc. (NYSE: COR) reported fiscal second-quarter 2026 results before the open on May 6, 2026, delivering a rare top-line miss alongside a guidance raise. Total revenue rose 3.8% year over year to $78.4 billion, falling short of the FactSet consensus estimate of $81.09 billion. Adjusted diluted EPS of $4.75 — up 7.5% from $4.42 in the prior-year quarter — also missed the Street’s $4.81 expectation. Despite the headline miss, management raised the full-year adjusted EPS guidance range, signaling continued confidence in second-half profitability. Shares fell roughly 6.3% in pre-market trading to $286.68 from a prior close of $305.90, valuing the company at approximately $56 billion.

Q2 Results: Revenue Miss but Margin Holds

The Q2 FY2026 quarter saw Cencora’s specialty drug distribution engine continue to grind forward, just not as quickly as analysts had modeled. The $2.7 billion gap to consensus revenue is meaningful for a company whose business model depends on high-volume turnover.

GAAP diluted EPS of $8.40 — nearly $3.65 above the prior-year period — looks dramatic, but the comparison is distorted. The reported figure includes a roughly $1.1 billion pre-tax remeasurement gain tied to the OneOncology acquisition, which is non-recurring and not a reflection of operating performance. The cleaner metric is adjusted diluted EPS at $4.75.

GAAP operating income reached $1.1 billion, up 10.3% year over year, while adjusted operating income climbed 6.0% to $1.3 billion. Adjusted operating income margin came in at roughly 1.66% — typical for pharmaceutical distribution, where high turnover, not gross margin, drives returns on capital.

Segment Breakdown: International Outpaces Domestic

The most notable detail in the quarter is the widening divergence between Cencora’s two main segments.

The U.S. business — at roughly 88% of consolidated revenue — was the primary source of the consensus miss. International, anchored by Alliance Healthcare’s European footprint, ran at more than four times the domestic growth rate on both revenue and adjusted operating income. International’s implied adjusted operating margin of about 2.3% is meaningfully higher than the U.S. segment’s 1.45%, lifting consolidated mix as the international book scales.

The “Other” segment was the lone soft spot on profitability, with adjusted operating income down 1.3% despite mid-single-digit revenue growth. At roughly 2.7% of consolidated revenue, however, the segment is too small to move the needle.

Full-Year Guidance Raised Despite the Miss

Management raised FY2026 adjusted diluted EPS guidance to a range of $17.65 to $17.90, up from a prior $17.45 to $17.75. Revenue growth guidance was maintained at 4% to 6%, and adjusted operating income growth guidance was held at 12% to 14%.

The math is striking: full-year adjusted operating income growth of 12% to 14% requires acceleration from the 6.0% pace delivered in Q2 FY2026. That implies the back half of the fiscal year (April–September 2026) must run materially hotter than the first half. The most plausible levers are continued specialty drug and oncology volume ramp, sustained international momentum, and U.S. expense discipline — the U.S. segment already delivered adjusted operating income growth of 5.6% on just 2.9% revenue growth in the quarter.

Net interest expense is guided at approximately $485 million for the year. Cencora also reaffirmed plans to repurchase $1 billion of stock by the end of calendar year 2026 — roughly 1.8% of equity value at the post-earnings price — providing a measured capital-return cushion as shares reset.

Key Signals for Investors

• The U.S. Healthcare Solutions deceleration to 2.9% revenue growth is the swing factor: if the domestic segment cannot reaccelerate in Q3 and Q4, the maintained 4%–6% full-year revenue range becomes difficult to defend.
• International’s 13% revenue growth and 13.7% adjusted operating income growth need to persist for management’s full-year operating income trajectory of 12%–14% to bridge the gap left by Q2.
• The OneOncology gain ($1.1 billion pre-tax) is non-recurring; investors should ignore the GAAP EPS optical lift and watch specialty/oncology volume contribution to U.S. adjusted operating income as the cleaner read on the platform’s earnings power.
• The $1 billion share repurchase, targeted for completion by December 31, 2026, signals management views the post-earnings drawdown as a buying opportunity; pace of execution is the credibility test.
• Q3 FY2026 results (covering April 1 – June 30, 2026) will be the first true checkpoint on whether Q2’s revenue softness was transitory or the start of a more durable slowdown.